Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors

Ratnakar Singh, Zeeshan Fazal, Andrea K. Corbet, Emmanuel Bikorimana, Jennifer C. Rodriguez, Ema M. Khan, Khadeeja Shahid, Sarah Joy Spinella, Michael J Spinella

Research output: Contribution to journalArticle

Abstract

A greater understanding of the hypersensitivity and curability of testicular germ cell tumors (TGCTs) has the potential to inform strategies to sensitize other solid tumors to conventional chemotherapies. The mechanisms of cisplatin hypersensitivity and resistance in embryonal carcinoma (EC), the stem cells of TGCTs, remain largely undefined. To study the mechanisms of cisplatin resistance we generated a large panel of independently derived, acquired resistant clones from three distinct parental EC models employing a protocol designed to match standard of care regimens of TGCT patients. Transcriptomics revealed highly significant expression changes shared between resistant cells regardless of their parental origin. This was dominated by a highly significant enrichment of genes normally repressed by H3K27 methylation and the polycomb repressive complex 2 (PRC2) which correlated with a substantial decrease in global H3K27me3, H2AK119 ubiquitination, and expression of BMI1. Importantly, repression of H3K27 methylation with the EZH2 inhibitor GSK-126 conferred cisplatin resistance to parental cells while induction of H3K27 methylation with the histone lysine demethylase inhibitor GSK-J4 resulted in increased cisplatin sensitivity to resistant cells. A gene signature based on H3K27me gene enrichment was associated with an increased rate of recurrent/progressive disease in testicular cancer patients. Our data indicates that repression of H3K27 methylation is a mechanism of cisplatin acquired resistance in TGCTs and that restoration of PRC2 complex function is a viable approach to overcome treatment failure.

Original languageEnglish (US)
Article number796
JournalCancers
Volume11
Issue number6
DOIs
StatePublished - Jun 8 2019

Fingerprint

Polycomb Repressive Complex 2
Epigenomics
Cisplatin
Down-Regulation
Methylation
Drug Therapy
Hypersensitivity
Histone Demethylases
Embryonal Carcinoma
Genes
Embryonal Carcinoma Stem Cells
Ubiquitination
Testicular Neoplasms
Standard of Care
Treatment Failure
Clone Cells
Testicular Germ Cell Tumor
Neoplasms

Keywords

  • Cisplatin
  • Epigenetics
  • H3K273me
  • Histone methylation
  • Polycomb repressive complex
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors. / Singh, Ratnakar; Fazal, Zeeshan; Corbet, Andrea K.; Bikorimana, Emmanuel; Rodriguez, Jennifer C.; Khan, Ema M.; Shahid, Khadeeja; Spinella, Sarah Joy; Spinella, Michael J.

In: Cancers, Vol. 11, No. 6, 796, 08.06.2019.

Research output: Contribution to journalArticle

Singh, Ratnakar ; Fazal, Zeeshan ; Corbet, Andrea K. ; Bikorimana, Emmanuel ; Rodriguez, Jennifer C. ; Khan, Ema M. ; Shahid, Khadeeja ; Spinella, Sarah Joy ; Spinella, Michael J. / Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors. In: Cancers. 2019 ; Vol. 11, No. 6.
@article{50f5ca0e5b5d46988bbf2363160fdd0a,
title = "Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors",
abstract = "A greater understanding of the hypersensitivity and curability of testicular germ cell tumors (TGCTs) has the potential to inform strategies to sensitize other solid tumors to conventional chemotherapies. The mechanisms of cisplatin hypersensitivity and resistance in embryonal carcinoma (EC), the stem cells of TGCTs, remain largely undefined. To study the mechanisms of cisplatin resistance we generated a large panel of independently derived, acquired resistant clones from three distinct parental EC models employing a protocol designed to match standard of care regimens of TGCT patients. Transcriptomics revealed highly significant expression changes shared between resistant cells regardless of their parental origin. This was dominated by a highly significant enrichment of genes normally repressed by H3K27 methylation and the polycomb repressive complex 2 (PRC2) which correlated with a substantial decrease in global H3K27me3, H2AK119 ubiquitination, and expression of BMI1. Importantly, repression of H3K27 methylation with the EZH2 inhibitor GSK-126 conferred cisplatin resistance to parental cells while induction of H3K27 methylation with the histone lysine demethylase inhibitor GSK-J4 resulted in increased cisplatin sensitivity to resistant cells. A gene signature based on H3K27me gene enrichment was associated with an increased rate of recurrent/progressive disease in testicular cancer patients. Our data indicates that repression of H3K27 methylation is a mechanism of cisplatin acquired resistance in TGCTs and that restoration of PRC2 complex function is a viable approach to overcome treatment failure.",
keywords = "Cisplatin, Epigenetics, H3K273me, Histone methylation, Polycomb repressive complex, Testicular cancer",
author = "Ratnakar Singh and Zeeshan Fazal and Corbet, {Andrea K.} and Emmanuel Bikorimana and Rodriguez, {Jennifer C.} and Khan, {Ema M.} and Khadeeja Shahid and Spinella, {Sarah Joy} and Spinella, {Michael J}",
year = "2019",
month = "6",
day = "8",
doi = "10.3390/cancers11060796",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

TY - JOUR

T1 - Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors

AU - Singh, Ratnakar

AU - Fazal, Zeeshan

AU - Corbet, Andrea K.

AU - Bikorimana, Emmanuel

AU - Rodriguez, Jennifer C.

AU - Khan, Ema M.

AU - Shahid, Khadeeja

AU - Spinella, Sarah Joy

AU - Spinella, Michael J

PY - 2019/6/8

Y1 - 2019/6/8

N2 - A greater understanding of the hypersensitivity and curability of testicular germ cell tumors (TGCTs) has the potential to inform strategies to sensitize other solid tumors to conventional chemotherapies. The mechanisms of cisplatin hypersensitivity and resistance in embryonal carcinoma (EC), the stem cells of TGCTs, remain largely undefined. To study the mechanisms of cisplatin resistance we generated a large panel of independently derived, acquired resistant clones from three distinct parental EC models employing a protocol designed to match standard of care regimens of TGCT patients. Transcriptomics revealed highly significant expression changes shared between resistant cells regardless of their parental origin. This was dominated by a highly significant enrichment of genes normally repressed by H3K27 methylation and the polycomb repressive complex 2 (PRC2) which correlated with a substantial decrease in global H3K27me3, H2AK119 ubiquitination, and expression of BMI1. Importantly, repression of H3K27 methylation with the EZH2 inhibitor GSK-126 conferred cisplatin resistance to parental cells while induction of H3K27 methylation with the histone lysine demethylase inhibitor GSK-J4 resulted in increased cisplatin sensitivity to resistant cells. A gene signature based on H3K27me gene enrichment was associated with an increased rate of recurrent/progressive disease in testicular cancer patients. Our data indicates that repression of H3K27 methylation is a mechanism of cisplatin acquired resistance in TGCTs and that restoration of PRC2 complex function is a viable approach to overcome treatment failure.

AB - A greater understanding of the hypersensitivity and curability of testicular germ cell tumors (TGCTs) has the potential to inform strategies to sensitize other solid tumors to conventional chemotherapies. The mechanisms of cisplatin hypersensitivity and resistance in embryonal carcinoma (EC), the stem cells of TGCTs, remain largely undefined. To study the mechanisms of cisplatin resistance we generated a large panel of independently derived, acquired resistant clones from three distinct parental EC models employing a protocol designed to match standard of care regimens of TGCT patients. Transcriptomics revealed highly significant expression changes shared between resistant cells regardless of their parental origin. This was dominated by a highly significant enrichment of genes normally repressed by H3K27 methylation and the polycomb repressive complex 2 (PRC2) which correlated with a substantial decrease in global H3K27me3, H2AK119 ubiquitination, and expression of BMI1. Importantly, repression of H3K27 methylation with the EZH2 inhibitor GSK-126 conferred cisplatin resistance to parental cells while induction of H3K27 methylation with the histone lysine demethylase inhibitor GSK-J4 resulted in increased cisplatin sensitivity to resistant cells. A gene signature based on H3K27me gene enrichment was associated with an increased rate of recurrent/progressive disease in testicular cancer patients. Our data indicates that repression of H3K27 methylation is a mechanism of cisplatin acquired resistance in TGCTs and that restoration of PRC2 complex function is a viable approach to overcome treatment failure.

KW - Cisplatin

KW - Epigenetics

KW - H3K273me

KW - Histone methylation

KW - Polycomb repressive complex

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=85068452255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068452255&partnerID=8YFLogxK

U2 - 10.3390/cancers11060796

DO - 10.3390/cancers11060796

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 6

M1 - 796

ER -